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Antennapedia and HIV transactivator of transcription (TAT)
"protein transduction domains" promote endocytosis of high
molecular weight cargo upon binding to cell surface
glycosaminoglycans
Abstract
Protein transduction domains (PTDs) are short basic peptide sequences present in many cellular and
viral proteins that mediate translocation across cellular membranes. PTDs have become widely used as
tools for the delivery of high Mr polypeptides, polynucleotides, or nanoparticles to cells in culture; and
even the transfer of cargo molecules to the tissue of live animals has been reported. These
cell-permeable peptides are functional when fused in-frame to recombinant polypeptides or when
chemically coupled to their cargo. The mechanism responsible for PTD-mediated membrane
translocation is controversially discussed and may vary among the various PTDs reported in the
literature. Thus direct physical interaction with membrane lipids resulting in vectorial delivery to cells
has been proposed for the Antennapedia (Antp) PTD, whereas uptake by the retroviral TAT
(transactivator of transcription) protein PTD seems to require cell surface-expressed
glycosaminoglycans. The view that PTD-mediated cellular uptake is energy-independent has been
dismissed recently as an artifact resulting from fixation of cells. The data reported here agree with and
further extend this work. They support the idea that certain PTDs promote cellular uptake via
endocytosis and require the expression of negatively charged glycosaminoglycans on the surface of the
target cells. Uptake of Antp PTD conjugates or peptide-derivatized liposomes was blocked by heparan
sulfate proteoglycans, whereas TAT-mediated uptake was inhibited by both heparin and dextran sulfate.
Mutant cells defective for glycosaminoglycan synthesis showed dramatically reduced Antp- or
TAT-mediated transmembrane transport confirming the role of these complex polysaccharides in
PTD-mediated cellular uptake. The fact that PTDs selectively interact with distinct glycosaminoglycan
species has implications for therapeutic applications and may allow targeting of selective tissues that
differ in their surface-expressed glycosaminoglycan patterns.
Antennapedia and HIV Transactivator of Transcription (TAT)
“Protein Transduction Domains” Promote Endocytosis of
High Molecular Weight Cargo upon Binding to
Cell Surface Glycosaminoglycans*□S
Received for publication, February 19, 2003, and in revised form, June 26, 2003
Published, JBC Papers in Press, June 30, 2003, DOI 10.1074/jbc.M301726200
Sandra Console‡§, Cornelia Marty‡§, Carlos Garcı´a-Echeverrı´a¶, Reto Schwendener‡,
and Kurt Ballmer-Hofer‡
From ‡Biomolecular Research, Paul Scherrer Institut, CH-5232 Villigen, Switzerland and ¶Oncology Research,
Novartis Pharma Inc., CH-4002 Basel, Switzerland
Protein transduction domains (PTDs) are short basic
peptide sequences present in many cellular and viral
proteins that mediate translocation across cellular
membranes. PTDs have become widely used as tools for
the delivery of high Mr polypetides, polynucleotides, or
nanoparticles to cells in culture; and even the transfer
of cargo molecules to the tissue of live animals has been
reported. These cell-permeable peptides are functional
when fused in-frame to recombinant polypeptides or
when chemically coupled to their cargo. The mechanism
responsible for PTD-mediated membrane translocation
is controversially discussed and may vary among the
various PTDs reported in the literature. Thus direct
physical interaction with membrane lipids resulting in
vectorial delivery to cells has been proposed for the
Antennapedia (Antp) PTD, whereas uptake by the retro-
viral TAT (transactivator of transcription) protein PTD
seems to require cell surface-expressed glycosaminogly-
cans. The view that PTD-mediated cellular uptake is
energy-independent has been dismissed recently as an
artifact resulting from fixation of cells. The data re-
ported here agree with and further extend this work.
They support the idea that certain PTDs promote cellu-
lar uptake via endocytosis and require the expression of
negatively charged glycosaminoglycans on the surface
of the target cells. Uptake of Antp PTD conjugates or
peptide-derivatized liposomes was blocked by heparan
sulfate proteoglycans, whereas TAT-mediated uptake
was inhibited by both heparin and dextran sulfate. Mu-
tant cells defective for glycosaminoglycan synthesis
showed dramatically reduced Antp- or TAT-mediated
transmembrane transport confirming the role of these
complex polysaccharides in PTD-mediated cellular up-
take. The fact that PTDs selectively interact with dis-
tinct glycosaminoglycan species has implications for
therapeutic applications and may allow targeting of se-
lective tissues that differ in their surface-expressed gly-
cosaminoglycan patterns.
Uptake of charged molecules or high molecular weight com-
pounds into live cells is hampered by the lipophilic nature of
the plasma membrane. Thus high amounts of drugs are often
required to maintain pharmacologically active concentrations
in the target tissue of an organism. The human immunodefi-
ciency virus (HIV)1-encoded transactivator of transcription
(TAT) protein rapidly crosses the plasma membrane of live
cells (1, 2). More recently, additional cellular and viral proteins
with similar features have been described, such as VP22, a
herpesvirus protein involved in regulating transcription, and
Antennapedia (Antp) a transcription factor discovered first in
insect cells. In all of these proteins, the activity of translocating
across cellular membranes is confined to a short stretch of less
than 20 amino acids highly enriched in basic residues. These
sequences are now called “protein transduction domains” or
PTD sequences and act independently from other protein mo-
tifs. They have been used both in vitro and in vivo to target
proteins, nucleic acid polymers, or nanoparticles (such as lipo-
somes) to cells (reviewed in Refs. 3–7).
The mechanism responsible for PTD-dependent membrane
translocation is controversially discussed and may vary among
the various PTDs. In recent papers, it has been proposed that
Antp peptide-mediated membrane translocation is an energy-
independent process and may be a direct consequence of PTD
association with membrane lipids (8, 9). This mechanism would
require the formation of transient micelles that are subse-
quently transferred to the cytoplasmic side of the membrane
where cargo molecules are then released. This concept has been
questioned in the meantime, and it has been demonstrated that
PTD translocation at low temperature is an artifact resulting
from the fixation of cells (10, 11). Other data suggest that, at
least for the TAT peptide, membrane translocation is mediated
by cell surface-expressed heparan sulfate glycosaminoglycans
(HPSGs) (12–16). A detailed study of the role of HPSGs in
TAT-mediated intracellular transport showed that TAT basic
peptide also interferes with the release of newly synthesized
HPSGs from cells (17).
Following this line of work, we investigated the uptake
mechanism of Antp and TAT PTD protein complexes. The
transport to cells by both PTDs occurred only at 37 °C and
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depended on the expression of negatively charged glycosamin-
oglycans on the surface of the target cells. PTD complexes
associated first with the cell surface and were then rapidly
translocated to cytoplasmic vesicles resembling early endo-
somes. After prolonged exposure of cells at 37 °C, the material
accumulated in intracellular vesicular structures. Liposomes
tagged with PTD peptides were similarly internalized within
the cells thereby improving their potential use for intracellular
drug delivery.
EXPERIMENTAL PROCEDURES
Materials—The antibodies for staining lysosomes were G1/139
against human Lamp1 (18) and G1/221 against human transferrin
receptor (19). Fluorescent avidin and streptavidin and secondary anti-
bodies were from Southern Biotech (Birmingham, AL). Glycosaminogly-
cans and dextran sulfate were from Sigma, except for heparin, which
was a kind gift from Dr. H. P. Wessel (Hoffman-La Roche). Soybean
phosphatidylcholine (SPC) was obtained from L. Meyer (Hamburg,
Germany). Cholesterol (Chol) was purchased from Fluka (Buchs, Swit-
zerland), 2-dipalmitoyl-sn-glycerol-3-phosphatidylethanolamine
(DPPE) from Sygena (Liestal, Switzerland), and 3,3-dioctadecyloxa-
carbocyanine perchlorate (DiO) from Molecular Probes (Leiden, The
Netherlands). Sulfo-SMCC was purchased from Pierce (Lausanne,
Switzerland).
The mouse melanoma cell line B16F1 was maintained in Dulbecco’s
modified Eagle’s medium plus 10% fetal bovine serum, 1% L-glutamine,
100 units/ml penicillin, 100 g/ml streptomycin and Nystatin. Wild type
CHO K1, CHO pgs A-677, and CHO pgs A-745 cells were from ATCC
(Manassas, VA) and were maintained in Ham’s F12 medium (20, 21).
Peptide Synthesis—The peptides were synthesized on a Milligen
9050 automated peptide synthesizer (continuous flow), employing the
fluorenylmethoxycarbonyl strategy and protocols from our laboratory
reported previously (22, 23). After completion of the syntheses, the
peptide resins were simultaneously cleaved and deprotected with tri-
fluoroacetic acid/water/ethanedithiol (76:4:20, v/v/v) for 3 h at room
temperature, and the crude compounds were purified by reverse-phase
medium chromatography on a C18 column (0.1% trifluoroacetic acid-
water/acetonitrile gradient). The purity of the peptides was verified by
reverse-phase analytical high pressure liquid chromatography, and the
identities of the final products were assessed by amino acid and mass
spectral analyses (matrix-assisted laser-desorption ionization time-of-
flight mass spectrometry (MALDI-TOF)) analyses. The analytical lin-
ear gradient was applied over 2.5 min consisting of acetonitrile, 0.09%
trifluoroacetic acid and water, 0.1% trifluoroacetic acid from 1:19 to 3:2
on a Chromolith SpeedROD RP-18e column (50  4.6 mm), at a flow
rate of 4.0 ml/min; detection at 215 nm; single peak at retention time 
1.45 min (TAT peptide) and retention time  2 min (Antp peptide).
Quantitative amino acid analyses of the peptides revealed the expected
amino acid compositions. MALDI-TOF (negative-ion mode) found
2031.5 (calculated 2031.5) for the TAT peptide and 2718.2 (calculated
2718.4) for the Antp peptide.
Internalization of TAT and Antennapedia Peptide Complexes in HeLa
Cells—HeLa cells were cultured on coverslips in Dulbecco’s modified
Eagle’s medium supplemented with 10% fetal bovine serum. Internal-
ization of peptide complexed with either fluorescein isothiocyanate
(FITC)-labeled avidin or streptavidin was performed as follows. A 1-M
solution of biotinylated peptide was preincubated with 1 M fluores-
cently labeled avidin or streptavidin at room temperature for 30 min
with or without inhibitory glycosaminoglycans (50 g/ml) in Opti-
MEM I. Peptide complexes were added to washed HeLa cells on cover-
slips in Opti-MEM I at 4 °C for 30 min. The cells were fixed in 3.7%
formaldehyde or incubated in fresh Opti-MEM I prewarmed to 37 °C for
the indicated times to follow protein transduction in the cells. The cells
were permeabilized with 0.25% Saponin for 3 min for costaining of
internalized FITC avidinpeptide with antibodies recognizing trans-
ferrin (a marker for early endosomes (19)) or Lamp1 (a lysosomal
protein (18)). 1% TRITC-labeled dextran was added as a marker for
fluid-phase endocytosis in the corresponding assays. The cells were
embedded in gelvatol and analyzed on a Zeiss Axiophot fluorescence
microscope with epi-illuminescence using a 40 NA 1.4 water immer-
sion lens. Photomicrographs were taken with a Kappa CF 8/1 CCD
camera; exposure time was 5 ms for all pictures in the series. Confocal
series were acquired with an LSM 410 confocal microscope (Zeiss,
Oberkochen, Germany). The Imaris software (Bitplane AG, Zu¨rich,
Switzerland) was used for image analysis.
Liposome Preparation and Modification—The liposomes were com-
posed of SPC:Chol:DPPE:DiO at a molar ratio of 1:0.2:0.035:0.004.
Small unilamellar liposomes were prepared by sequential filter extru-
sion of multilamellar liposomal preparations in Soerensen phosphate
buffer (SPB, 13 mM KH2PO4, 54 mM NaHPO4, pH 7.4) through Nucleo-
pore membranes (Sterico, Dietikon, Switzerland) of 0.2 m and 0.1 m
pore diameter with a Lipex extruder (Lipex Biomembranes Inc., Van-
couver, British Columbia, Canada). Size and stability of the liposomes
were analyzed with a particle sizer (Nicomp Model 370, Santa Barbara,
CA). For peptide modification, liposomes in SPB were incubated with
crystalline sulfo-SMCC at a molar ratio for amino groups to maleimide
groups of 1:5 for 30 min at 30 °C. Excess sulfo-SMCC was removed by
dialysis overnight at 4 °C against SPB. 3 mg of PTD peptide or cysteine
as a control were incubated with 1 ml of sulfo-SMCC-modified lipo-
somes for 20 h at room temperature in 2 mM tributylphosphine under
an argon atmosphere. Nonreacted peptide was removed by dialysis
against SPB.
Flow Cytometry—Cells (2  105 cells in 12-well plates) were grown
for 24 h at 37 °C. The medium was removed, and the cells were incu-
bated in serum-free Opti-MEM I for 30 min at 37 °C. Before addition to
the cells, PTDstreptavidin complexes or PTD-derivatized liposomes
were preincubated with or without 20 g/ml polysaccharide at room
temperature for 15 min. The cells were incubated with the complex in
serum-free Opti-MEM I at 37 °C. Complexes were removed, and the
cells were cultured in growth medium as described above for 90 min at
37 °C. The cells were washed with PBS (0.137 M NaCl, 2.68 mM KCl,
8.09 mM Na2HPO4, 1.76 mM KH2PO4, pH 7.4), detached from the plates
with 10 mM EDTA in PBS, washed in PBS, and either used directly or
after fixation in 3.7% formaldehyde in PBS for flow cytometric analysis.
Internalization of PTD complexes or liposomes was determined in a
FACScan flow cytometer (BD Biosciences). 10,000 cells were analyzed
per data point, and all experiments were carried out in triplicate.
RESULTS
PTD peptide sequences derived from TAT and Antp were
SGYGRKKRRQRRRC and SGRQIKIWFQNRRMKWKKC, re-
spectively. They were both chemically synthesized, biotiny-
lated at the N terminus, and carried a C-terminal cysteine
residue for chemical coupling to cargo molecules. The Ser-Gly
dipeptide at the N terminus was used as a spacer between the
peptide and biotin. These peptides were efficiently delivered to
cells and could be detected with FITC-labeled avidin or strepta-
vidin in fixed and permeabilized cells as described earlier (8)
(data not shown).
PTD-mediated cellular uptake was next investigated with
FITC-labeled avidin or streptavidin conjugated with biotiny-
lated PTD peptide. Intracellular transport of this complex was
studied in a variety of cell lines such as HeLa, B16 melanoma,
and CHO cells. Complexes were rapidly taken up by all cell
types tested. Figs. 1 and 2 show representative data for HeLa
cells. FITC-labeled avidin or streptavidin was first preincu-
bated for 15 min with either biotinylated Antp or TAT peptide
followed by incubation with cells at 0 °C. The labeled material
accumulated in small patches on the surface of the cells (Figs.
1A and 2A). FITC-labeled avidin or streptavidin did not asso-
ciate with cells in the absence of PTD peptide or when bound to
a peptide lacking a PTD domain (Figs. 1O, 2O, and data not
shown). This indicates that membrane binding was a specific
event mediated by PTD peptide.
Cells incubated with FITC-avidinpeptide complexes were
then washed and further incubated at 37 °C in growth medium
to induce internalization. As seen in Figs. 1B and 2B, fluores-
cently labeled material was internalized within minutes and
accumulated in vesicular structures resembling early endo-
somes. These vesicles partially colocalized with TRITC-labeled
dextran added during the chase period at 37 °C as a marker for
fluid-phase endocytosis (data given in supplemental Fig. A). A
marker protein for early endosomes, the transferrin receptor,
showed similar localization as avidinPTD complexes (data
given in supplemental Fig. B). After incubation for 1–3 h at
37 °C, the material was confined to intracellular vesicles (Figs.
1C and 2C). Antp complexes showed partial colocalization with
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lysosomes (data given in supplemental Fig. B), whereas TAT
accumulated in vesicular structures located at the cell periph-
ery (data given in supplemental Fig. C).
To prove that PTD complexes were internalized during the
chase period at 37 °C, cells were analyzed by confocal micros-
copy. Z-sections through cells (Figs. 1 and 2, Z⁄X and Z⁄Y)
showed that the material was predominantly associated with
the extracellular face of the plasma membrane before the chase
(Figs. 1D and 2D). Upon extended incubation at 37 °C, both
Antp (Fig. 1, F and G) and TAT (Fig. 2, F and G) complexes
were transferred to intracellular vesicular structures, whereas
after a 10-min chase, most of the material remained on the
extracellular surface. Taken together, our data show that both
PTDs initially bind to the cell surface in a temperature-
independent way where they cluster in small patches on the
extracellular side of the plasma membrane. Upon shifting the
cells to 37 °C, the material was internalized in intracellular
vesicular structures by a mechanism resembling fluid-phase
endocytosis.
We next investigated the mechanism responsible for PTD-
mediated cellular uptake. Chinese hamster ovary (CHO) cells
were incubated with FITC-labeled streptavidinPTD complex
for 90 min at 37 °C, washed, removed from tissue culture plates
with EDTA solution, washed again in PBS, and submitted to
flow cytometric analysis. Fig. 3A shows that heparin inhibited
association with and internalization of TAT complexes by 60–
70%, whereas uptake of streptavidinAntp complex was re-
duced by 40–50%. Dextran sulfate inhibited uptake of TAT but
not of Antp complexes. Other glycosaminoglycans such as chon-
droitin sulfate A, B, and C and hyaluronic acid had no effect on
PTD-mediated cellular uptake (data not shown). No cellular
uptake was observed in controls performed with FITC-labeled
streptavidin in the absence of PTD peptide (Fig. 3A). It has
recently been shown that fixation of cells promotes artifactual
FIG. 2. Cell binding and internalization of FITC-labeled avidinTAT peptide complexes. Treatment and analysis of cells are as described
in Fig. 1.
FIG. 1. Cell binding and internalization of FITC-labeled avidinAntp peptide complexes. Cells were treated with FITC-avidinAntp
complex as described under “Experimental Procedures.” A, HeLa cells were incubated for 30 min at 0 °C with PTD complex, washed, and further
incubated at 37 °C for 60 min (B) and 180 min (C). O, shows a photomicrograph of cells incubated with FITC-avidin in the absence of peptide.
Photomicrographs were taken on a Zeiss Axiophot microscope. D–G, show Z/X- and Z/Y-sections constructed from a confocal series through
representative cells. 12 sections of 600–900 nm were taken for each series, and Z-sections were constructed with Imaris software. Z-sections were
taken at a line running through the midpoint of the XY plane. D, analysis of a cell treated as in A. E, shows cells chased for 10 min at 37 °C after
PTD binding. F and G, show a similar analysis performed with cells treated for 60 and 180 min at 37 °C, respectively. Bar represents 50 m.
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association of PTD peptides with cells (10). To rule this out for
our experiments, we analyzed cells incubated with PTD com-
plex before and after fixation by flow cytometry. As shown in
Fig. 3C, the amount of PTD complex bound to cells and inhi-
bition by heparin was not changed.
Similar experiments were then performed with PTD-deriva-
tized phosphatidylcholine liposomes. The PTD peptides were
coupled via a cysteine residue to maleimide derivatized lipids
(24). As shown in Fig. 3B, uptake of TAT peptide-modified
liposomes was increased 10-fold, whereas Antp-derivatized li-
posomes were internalized 50 times more efficiently than con-
trol liposomes modified with cysteine instead of a PTD peptide.
The difference in uptake efficiency presumably results from the
fact that TAT-derivatized liposomes tend to form large aggre-
gates that are less well internalized. Uptake of liposomes into
CHO cells was blocked by heparin and dextran sulfate but not
by other glycosaminoglycans such as chondroitin A (Fig. 3B) or
chondroitins B and C and hyaluronic acid (data not shown).
Taken together, these data suggest that cell surface-expressed
glycosaminoglycans, in particular HPSGs, are required for TAT
and Antp PTD-mediated cellular uptake of proteins and lipo-
somes. Dextran sulfate polymers and heparan sulfates inhib-
ited uptake by TAT, whereas Antp-dependent protein uptake
was blocked only by heparan sulfates. This suggests differen-
tial binding of these peptides to negatively charged extracellu-
lar glycosaminoglycans and also indicates that TAT and Antp
PTDs rely on different oligosaccharides for initial membrane
binding. PTD-derivatized liposome uptake was indiscrimi-
FIG. 3. A, Antp and TATstreptavidin complex uptake into CHO cells is inhibited by polysaccharides. CHO cells were incubated for 90 min at
37 °C with FITC-labeled Antp or TAT streptavidin complex in the absence or presence of heparin (Hep) or dextran sulfate (Dex). As a control, cells
were treated with FITC-labeled streptavidin alone. Cells were washed, removed from tissue culture plates, fixed, and submitted to flow cytometric
analysis. 10,000 cells were analyzed for each data point in triplicate. Strp, streptavidin. Error bars show mean  S.D. for each triplicate. B, Antp-
and TAT-derivatized liposome uptake into B16 cells is inhibited by polysaccharides. B16 melanoma cells were incubated for 90 min at 37 °C with
FITC-labeled Antp- or TAT-derivatized liposomes with or without heparin, dextran sulfate, or chondroitin sulfate A. Cells were collected and
analyzed as in A. C, uptake of PTD complexes into CHO cells. The experiment was performed as in B, and the cells were either directly processed
for cytofluorometric analysis or fixed as described under “Experimental Procedures.”
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nately blocked by inhibitory polysaccharides such as dextran
sulfate and heparin.
To corroborate these findings, we investigated PTD uptake
into mutant CHO cells deficient in glycosaminoglycan synthe-
sis. Neither Antp nor TAT peptide complexes were efficiently
internalized in the mutant cell line (pgs A-745) lacking UDP-
D-xylose:serine -1,3-D-xylosyltransferase (21) (Fig. 4). These
cells are deficient in the synthesis of all proteoglycans. A sec-
ond mutant (pgs A-677) expressing reduced amounts of HPSG
because of an 10-fold reduction in N-acetylglucosaminyl-
transferase and glucuronosyltransferase (20) showed a reduc-
tion in the uptake of Antp but not of TATstreptavidin com-
plexes. This suggests that the low amount of HPSG expressed
by these cells still allowed PTD-mediated cellular uptake.
DISCUSSION
The data presented here show that the major route for TAT
and Antp peptide-mediated cellular uptake of protein mole-
cules and nanoparticles is endocytosis. Uptake by these PTDs
was temperature-dependent, indicative of a step requiring en-
ergy. The material that initially accumulated on the cell sur-
face in small patches (a process that was temperature-independ-
ent) was then followed by internalization in intracellular
vesicular structures. The nature of these patches is unclear;
they may represent plasma membrane microdomains such as
lipid rafts that are enriched in particular membrane proteins
carrying, for instance, HPSG polysaccharide chains. The route
and kinetics of uptake are similar to those followed by markers
for fluid-phase endocytosis such as fluorescent dextran
conjugates.
Uptake of avidin or streptavidinPTD complexes prepared
with either Antp or TAT peptide was blocked by negatively
charged high Mr glycosaminoglycans. TAT-mediated binding
was blocked by heparan and dextran sulfate, whereas Antp-de-
pendent uptake was blocked only by heparan sulfate. This
suggests that the basic character of PTDs promotes their in-
teraction with negatively charged complex sulfated glycosami-
noglycans exposed on the surface of cells. Uptake of both Antp
and TAT PTD-derivatized liposomes was similarly blocked by
heparin and dextran sulfate. The fact that cells deficient in
glycosaminoglycan synthesis showed reduced PTD uptake fur-
ther supports this notion. Specificity of the various PTDs for
different types of glycosaminoglycans may arise from the pos-
itive charge distribution in various PTDs; in other words, high
affinity interaction with negatively charged sulfated polysac-
charides expressed on the cell surface may require proper
alignment with the positive charges on a particular PTD. The
possibility that PTDs discriminate between different surface-
expressed glycosaminoglycans has been discussed earlier for
TAT (12–14, 16), and the role that heparan sulfate oligosaccha-
rides play in receptor binding and internalization has also been
investigated in other molecules, e.g. decorin (25). Finally,
Sandgren et al. (17) recently published work in which they
investigated the role of HPSGs in TAT-mediated cellular up-
take in detail. Differential interaction of PTDs with glycosami-
noglycans might open new possibilities for the delivery of re-
agents to specific tissues using more selective PTD sequences.
Further optimization of PTD peptides might thus improve their
translocation efficiency and may even allow the development of
tissue-specific PTDs (26).
The exact localization of cell-associated PTD complexes has
not always been critically evaluated in earlier work. We there-
fore analyzed confocal micrographs such as those shown in
Figs. 1 and 2 with an image-processing software. Z-sections of
confocal data sets show that fluorescent material initially ac-
cumulated in patches on the cell surface, in particular at sites
of cell-cell contact. As early as 10 min after shifting cells to a
high temperature, fluorescent material appeared in intracellu-
lar vesicular structures resembling endosomes. Partial colocal-
ization of PTD complexes with a marker for fluid-phase endo-
cytosis further suggests that uptake is through endocytosis, as
proposed earlier (1, 2). 1–2 h after incubation at 37 °C,
PTDcargo complexes accumulated in intracellular vesicular
structures. In the case of TAT, these vesicles were localized
close to the cell periphery, whereas Antp PTD complexes
showed perinuclear staining partially overlapping with a lyso-
somal marker. The route of cell entry and the turnover of
TATcargo complexes inside cells have also been investigated in
detail recently (17). These authors showed that cellular uptake
of TATPTD complexes was via endocytosis and that the com-
plexes were subsequently targeted to the nucleus. Together
with our data, this suggests that TAT and Antp PTDs target
their cargo to different cellular organelles.
Cellular uptake by Antp PTD sequences has not been inves-
tigated in detail so far. It has been proposed that Antp peptide
directly interacts with membrane lipids (6, 9), a finding that we
and others have not been able to confirm (27).2 We cannot
exclude the possibility, however, that the exact route of cell
entry and the transfer to intracellular vesicles may differ for
various PTDs. It will be of crucial importance for the further
development of PTD technology to dissect these pathways for
all PTD sequences, as each PTD might be destined for a specific
cellular compartment.
Liposomes are useful for the delivery of fragile reagents that
are rapidly degraded in the bloodstream. The drawback is that
the release of the liposomal content into target cells is limited
by the slow uptake of these vehicles into cells, and little is
known about the mechanism of liposome-mediated drug deliv-
ery. It is generally assumed that liposomes release their con-
tent upon fusion with intracellular membranes. We show here
that uptake of PTD-tagged liposomes is dramatically acceler-
ated when compared with control liposomes. This is in agree-
2 S. Console, C. Marty, C. Garcı´a-Echeverrı´a, R. Schwendener, and K.
Ballmer-Hofer, unpublished work.
FIG. 4. Antp and TATavidin complex uptake into CHO wild
type and mutant cells. CHO K1 wild type (pgs A-745 and pgs A-677)
mutant cells were incubated for 90 min at 37 °C with FITC-labeled
Antp or TATstreptavidin complex followed by analysis as described for
Fig. 3A. Av, FITC-avidin.
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ment with earlier work where similarly modified liposomes
have been shown to be efficiently internalized in cells even at
low temperature (28). A detailed analysis of the intracellular
localization of liposomes was, however, not performed in this
study. Based on the data shown here and on recently published
work (10), it is possible that liposomes associated with cells at
low temperature (as shown in that study) were actually bound
to the cell surface rather than being translocated to cells.
In summary, our study extends recently published work (10,
11, 17) and shows that PTD peptides derived from either HIV
TAT or Antennapedia promote cellular uptake of cargo through
endocytosis. PTD complexes initially accumulate on the surface
of target cells and are subsequently translocated across the
plasma membrane upon incubation of cells at 37 °C but not at
0 °C. The earlier proposal that PTD peptides penetrate mem-
branes upon direct interaction with the lipid bilayer, although
not formally excluded, seems not to apply for uptake of the high
Mr cargo molecules used here (Ref. 29, and reviewed in Ref. 6).
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